REBINNO DE ALEX J

PBM Formulary:

Duration: July 2023 – March 2024 (9 months)

• Developed and executed end-to-end (E2E) test scenarios to validate complex business logic and data models, ensuring 100% compliance with system requirements.
• Led integration testing between the core configuration engine and the claim adjudication system to verify seamless data exchange and functional interoperability.
• Managed a comprehensive regression testing suite for monthly system updates, preventing functional regressions and ensuring the stability of existing adjudication rules.
• Performed backend data validation using SQL to verify the integrity of master data mappings and pricing tables, identifying discrepancies before production deployment.
• Partnered with Product Owners to define Acceptance Criteria (AC) and User Stories, ensuring all features were testable and met quality benchmarks.
• Impact: Improved system processing accuracy by 18% and reduced post-release defects (rejections) by 20% through rigorous validation.

Commercial Drug Utilization & Analytics Platform

Duration: April 2024 – Jan 2025 (10 months)

• Authored and managed detailed Test Plans and Test Cases for a high-traffic analytics and monitoring platform, focusing on data visualization and reporting accuracy.
• Implemented a standardized regression testing framework to verify that UI enhancements and platform upgrades did not compromise the accuracy of historical data reports.
• Orchestrated Sprint Reviews and UAT sessions, ensuring all deliverables met the "Definition of Done" and aligned with stakeholder quality expectations.
• Impact: Enhanced reporting precision for high-value data and improved overall system reliability, contributing to a 15% reduction in operational waste.

Pharmaceutical digital marketing:

Duration: Feb 2025 – November 2025

• Served as the primary point of contact for the Berlin-Chemie account, leading client servicing and project management efforts.
• Collaborated with global teams of product managers to ensure quality, compliance, and value during the creation, revision, and review processes of medical affairs content.
• Defined acceptance criteria, authored user stories, and supported backlog refinement.
• Impact: Successfully grown the account 30% QoQ.